Sort   by:  
 Page size 
UnknownNASH-inducing Diets in Gottingen Minipigs.
Not available
S-EPMC7212300 | biostudies-literature
MetabolomicsDeficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease
Non-alcoholic fatty liver is the most common liver disease worldwide. Here, we show that the mitochondrial protein mitofusin 2 (Mfn2) protects against liver disease. Reduced Mfn2 expression was detected in liver biopsies from patients with non-alcoholic steatohepatitis (NASH). Moreover, reduced Mfn2...
2018-01-25 | MTBLS600 | MetaboLights
ProteomicsMetabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis
Non-alcoholic fatty liver disease is now considered the most common form of chronic liver disease. It is a complex metabolic disease that silently progresses into non-alcoholic steatohepatitis (NASH). In fact, NASH is the tipping point for pericellular fibrosis, cirrhosis and hepatocellular carcinom...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2021-08-19 | MSV000088003 | MassIVE
MetabolomicsDT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates

Nonalcoholic steatohepatitis (NASH) prevalence is rising with no pharmacotherapy approved. A major hurdle in NASH drug development is the poor translatability of preclinical studies to safe/effective clinical outcomes, and recent failures highlight a need to identify new targetable pathways. Dysr...

2023-04-13 | MTBLS5005 | MetaboLights
TranscriptomicsHepatic transcriptomic changes during non-alcoholic steatohepatitis (NASH)-associated liver carcinogenesis in mice
Hepatocellular carcinoma (HCC), which accounts for 90% of all primary livers tumors, is the fourth most common cancer in the world. The development of HCC is a long-term and complex process, and uncovering the molecular mechanisms associated with HCC development is critical for the disease diagnosi...
ORGANISM(S): Mus musculus 
2016-06-22 | E-GEOD-83596 | biostudies-arrayexpress
ProteomicsmARC1 knockdown protects liver from diet-induced NASH in mouse
Human genetic studies have identified several MARC1 variants as protective against non-alcoholic fatty liver diseases (NAFLD). The MARC1 variants are associated with reduced lipid profiles, liver enzymes, and liver-related mortality. However, the role of mitochondrial amidoxime reducing component 1 ...
ORGANISM(S): Mus Musculus (ncbitaxon:10090) 
2023-04-28 | MSV000091820 | MassIVE
TranscriptomicsPost-transplant (non-alcoholic steatohepatitis) NASH compared with transplanted normal controls
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease that ranges from simple steatosis, to inflammatory form non-alcoholic steatohepatitis (NASH), cirrhosis, and up to hepatocellular carcinoma. While NASH usually takes decades to develop at a rate of one stage per seven years...
ORGANISM(S): Homo sapiens 
2022-05-09 | E-MTAB-11688 | biostudies-arrayexpress
TranscriptomicsExpression data from mouse liver treated with metformin
Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes. We examined the effects of metformin, commonly used to treat patients with type 2 diabetes, on liver pathology in a non-diabetic NASH mouse model. Eight-week-old C57...
ORGANISM(S): Mus musculus 
2012-02-21 | E-GEOD-35961 | biostudies-arrayexpress
UnknownThe Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.
Not available
S-EPMC9300564 | biostudies-literature
MetabolomicsFirst-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure

Diminished hepatocyte regeneration is a key feature of acute and chronic liver diseases and after extended liver resections, resulting in the inability to maintain or restore a sufficient functional liver mass. Therapies to restore hepatocyte regeneration are lacking, making liver transplantation...

2024-09-23 | MTBLS9434 | MetaboLights
Sort   by:  
 Page size